Pomalidomide-PEG2-Alkyne

Background Introduction

Pomalidomide-PEG2-Alkyne is a synthetic bifunctional molecule designed for use in targeted protein degradation platform development, such as PROTACs (Proteolysis Targeting Chimeras). This compound combines pomalidomide, a well-established cereblon (CRBN) E3 ligase ligand, with a polyethylene glycol (PEG2) linker ending in an alkyne functional group. The unique structure allows for bioorthogonal conjugation and flexible linker design, facilitating the generation of novel chemical tools for biomedical research and drug discovery.

Mechanism

The mechanism of action for Pomalidomide-PEG2-Alkyne involves the recruitment of the E3 ubiquitin ligase complex through its pomalidomide moiety, which specifically binds to cereblon (CRBN). The PEG2 linker offers optimal spatial flexibility and solubility, bridging the ligase ligand with an alkyne group. This terminal alkyne enables copper-catalyzed azide-alkyne cycloaddition (CuAAC) 'click chemistry' for efficient conjugation with a target-binding moiety or other biomolecules. In PROTACs, this bifunctional approach enables the proximity-induced ubiquitination and subsequent proteasomal degradation of proteins of interest.

Applications

Pomalidomide-PEG2-Alkyne serves as a versatile building block for the synthesis of PROTACs and other targeted protein degradation tools. Its applications include developing custom PROTAC molecules for preclinical target validation, chemical biology research, and early drug discovery. The alkyne functionality allows rapid conjugation to azide-containing ligands, peptides, or probes, enabling streamlined assembly of dual-function molecules. This product is ideal for academic and pharmaceutical researchers focused on modulating undruggable targets, studying protein function, and advancing next-generation therapeutics through the induced degradation approach.

• Alkyne-functionalized linker enables efficient click chemistry conjugation for versatile PROTAC development.
• Pomalidomide moiety ensures high affinity and selectivity for CRBN E3 ligase, facilitating effective target protein degradation.

Pomalidomide-PEG2-Alkyne serves as a versatile E3 Ligase Ligand-Linker Conjugate in PROTACs, facilitating targeted protein degradation by linking an E3 ligase ligand to a protein of interest. The following provides a detailed description of this molecule, emphasizing its linker, ligand, and reactive site characteristics.

Linker: The linker in Pomalidomide-PEG2-Alkyne is a polyethylene glycol (PEG2) chain, which offers moderate flexibility and optimal length for efficient spatial orientation. This non-cleavable linker ensures stable conjugation, enhancing the overall efficacy and selectivity of the PROTAC.

Ligand: The ligand component is derived from pomalidomide, a thalidomide analog known for its high affinity and specificity towards cereblon, an E3 ubiquitin ligase. This structural characteristic ensures effective recruitment of the E3 ligase complex, promoting targeted protein ubiquitination.

Reactive Site: The alkyne functional group serves as the reactive site, enabling click chemistry reactions such as copper-catalyzed azide-alkyne cycloaddition (CuAAC) with azide-functionalized target protein ligands. This site provides a robust and efficient coupling mechanism, facilitating the formation of stable conjugates.

Recommended Target Protein Ligand: An azide-functionalized warhead is recommended for compatibility with Pomalidomide-PEG2-Alkyne, offering the advantage of bioorthogonal reactivity that minimizes interference with biological systems. This warhead can be employed in experimental studies to degrade proteins implicated in disease pathways, providing a powerful tool for probing protein function and validating therapeutic targets.